King’s College London has launched a UK clinical trial, Pathway, to evaluate the risks and benefits of puberty blockers for roughly 220 children under 16 experiencing gender incongruence. The study follows the ban on prescribing the drugs outside research settings after the Cass review highlighted limited evidence on safety. Participants will receive comprehensive medical and psychological assessments before being randomly assigned to begin treatment immediately or after 12 months. Researchers w